TechBoRCLabs is committed to advancing scientific innovation in the field of mental health and substance use therapeutics. As we transition away from blockchain technologies (IT), our focus centers on rigorous research (RC) into arylcyclohexylamines and their potential to address unmet clinical needs.
Drawing on more than three decades of observation and analysis, we aim to identify and develop novel therapeutic agents that demonstrate strong efficacy without relying on traditional 5 HT1A/2A receptor agonists or the hallucinogenic effects associated with psychedelic compounds.
Our mission is to discover a molecule capable of delivering the transformative benefits of the psychedelic experience while remaining accessible, non hallucinogenic, and clinically practical for individuals who may be discouraged by or unsuitable for conventional psychedelic therapies
